"The advantages of mRNA vaccines include ability to create a highly precise type of protein to elicit the correct antibodies, to elicit T cell responses that are Th1 predominant, and the rapidity of manufacturing. Of course, disadvantages include the novel nature of both mRNA and DNA vaccines without any licensed vaccine with either technology to date and lack of experience for mass production."
P.-H. Lambert, D. M. Ambrosino, S. R. Andersen et al., Consensus summary report for CEPI/BCMarch 12–13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines, Vaccine, https://doi.org/10.1016/j.vaccine.2020.05.064
Hedley, I've watched several of your appearances, and you and Mike Dakkak did indeed have an interesting discussion and, perhaps, among the more comprehensive concerning manufacturing and distribution. Your point (above) alleging a *fraudulent* supply chain deserves a wider audience. I have referred your comments to a former Federal prosecutor (US) and to others as opportunities have arisen. Surely, you are aware of Kevin McKernan. It is hard *not* to see your work as complementary. Peter McCullough posted his interview with McKernan (07-27-2023) on his Substack. The interview is (at the moment) subscribers only, but the description alone is suggestive.
Yes, I have been on a call with Kevin McKernan and Peter McCullough knows of me, but for some reason, if you aren't a 'scientist' or 'doctor', there's little interest. Hopefully things will change over time...!
"The advantages of mRNA vaccines include ability to create a highly precise type of protein to elicit the correct antibodies, to elicit T cell responses that are Th1 predominant, and the rapidity of manufacturing. Of course, disadvantages include the novel nature of both mRNA and DNA vaccines without any licensed vaccine with either technology to date and lack of experience for mass production."
P.-H. Lambert, D. M. Ambrosino, S. R. Andersen et al., Consensus summary report for CEPI/BCMarch 12–13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines, Vaccine, https://doi.org/10.1016/j.vaccine.2020.05.064
Hedley, I've watched several of your appearances, and you and Mike Dakkak did indeed have an interesting discussion and, perhaps, among the more comprehensive concerning manufacturing and distribution. Your point (above) alleging a *fraudulent* supply chain deserves a wider audience. I have referred your comments to a former Federal prosecutor (US) and to others as opportunities have arisen. Surely, you are aware of Kevin McKernan. It is hard *not* to see your work as complementary. Peter McCullough posted his interview with McKernan (07-27-2023) on his Substack. The interview is (at the moment) subscribers only, but the description alone is suggestive.
Yes, I have been on a call with Kevin McKernan and Peter McCullough knows of me, but for some reason, if you aren't a 'scientist' or 'doctor', there's little interest. Hopefully things will change over time...!
And 25 years skip in testing...